Cempra presents new data on anti-microbials

Cempra Pharmaceuticals gave poster presentations last week on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate. The presentations were made at the 20th European Congress of Clinical Microbiology and Infectious Disease in Vienna, Austria.

CEM-101 has shown a broad spectrum of activity and high potency against respiratory and other serious pathogens in both in vitro and in vivo studies. The results from the first Phase I dose escalation study demonstrated that doses of CEM-101 from 200 to 600 mg were safe and well tolerated in healthy subjects and that the compound's pharmacokinetic profile is supportive of once-daily dosing.

Despite being available for over 40 years in Europe, sodium sodium fusidate (TAKSTA, CEM-102) demonstrated sustained activity against S. aureus including methicillin-resistant strains indicating that the compound is not highly susceptible to resistance development.

- read this Cempra release for more

Related Articles:
Cempra Pharmaceuticals - Top 20 Biotech VC Deals of 2009
Cempra rounds up $46M for antibiotic work

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.